ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0RDV Grifols SA

9.4875
0.00 (0.00%)
30 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Grifols SA LSE:0RDV London Ordinary Share PRF UNDATED EUR 0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.4875 9.28 9.695 17,332 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Grifols 2019 Annual Report on Form 20-F Filed With the SEC on April 6, 2020

06/04/2020 2:30pm

PR Newswire (US)


Grifols (LSE:0RDV)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Grifols Charts.

BARCELONA, Spain, April 6, 2020 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 6, 2020. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2019.

 

Grifols Logo

 

Form 20-F can be accessed electronically through the Grifols website at http://www.grifols.com/en/investors.The Form 20-F is also available on the SEC's website at http://www.sec.gov.

Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at investors@grifols.com to the attention of Grifols' Investor Relations, Re: 2019 Annual Report on Form 20-F.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information: www.grifols.com

Cision View original content:http://www.prnewswire.com/news-releases/grifols-2019-annual-report-on-form-20-f-filed-with-the-sec-on-april-6-2020-301035774.html

SOURCE Grifols, S.A.

Copyright 2020 PR Newswire

1 Year Grifols Chart

1 Year Grifols Chart

1 Month Grifols Chart

1 Month Grifols Chart